Compass Therapeutics, Inc. CMPX 深 沪
交易中 10-01 11:05:57 美东时间
0.9939
-0.046
-4.43%
华盛通- 最 高1.05
- 今 开1.03
- 成交量 93.50万股
- 最 低 0.9917
- 昨 收 1.04
- 总市值 1.79亿
- 52周最高 6.88
- 市盈率 静 --
- 换手率 0.52%
- 52周最低 0.9917
- 委 比 97.92%
- 总股本 1.80亿
- 历史最高 6.88
- 量 比 1.09
- 振 幅 5.61%
- 历史最低 0.765
- 每 手 1
- 风险率 1.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Compass Therapeutics shares are trading lower after the company announced that the FDA recommended it conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application submission for tovecimig in patients with previously treated, advanced biliary tract cancer
Compass Therapeutics shares are trading lower after the company announced that the FDA recommended it conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application submission for tovecimig in patients with previously treated, advanced biliary tract cancer
09-22 20:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6
Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.
08-08 00:58
Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 7.14 percent increase over losses of $(0.14) per share from the same period last year.
08-06 19:56
Compass Therapeutics Abstract Accepted For Oral Presentation At Upcoming European Society For Medical Oncology Congress
Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled "A randomized trial of paclitaxel ± tovecimig in previously treated pat...
07-17 22:47
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Compass Therapeutics announced that its abstract on a randomized trial of paclitaxel ± tovecimig in advanced biliary tract cancer has been accepted for an oral presentation at the ESMO Congress 2026 in Madrid. The presentation will discuss results from the Phase 2/3 COMPANION-002 trial, focusing on tovecimig, a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel. The session will be held on October 24, 2026, from 10:15am to 11:45am ...
07-17 14:42
Compass Showcases Promising Tovecimig Data, Eyes Commercialization
Compass Therapeutics ( ($CMPX) ) has shared an announcement. On July 1, 2026, C...
07-02 05:30
Compass Therapeutics Adopts Second Amended and Restated Bylaws
Compass Therapeutics ( ($CMPX) ) has provided an update. On June 22, 2026, Comp...
06-23 18:50
